COLUMBUS, Ohio–(BUSINESS WIRE)–Clarametyx Biosciences Inc. (“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the appointment of David Richards as the Company’s Chief Executive Officer (CEO), succeeding co-Founder and current CEO Michael Triplett, Ph.D., who will remain on the company’s Board of Directors. In addition, the Company has appointed Larry Edwards to its Board of Directors. These appointments are effective immediately.
“Now is the optimal time for Dave to take the helm at Clarametyx as we generate momentum in the development of our novel antibody technology platform. He brings not only clear domain expertise based on years of biofilm research, but also a refined entrepreneurial mindset with involvement in a series of successful ventures in recent years,” said Triplett. “Further, the expansion of our Board bolsters our focus on the next phase of our journey as we pursue active clinical development and strategic growth planning.”
Richards has served as Chief Business Officer since the company’s inception. Prior to his tenure at Clarametyx, he served in operational and general counsel roles for Aclipse Therapeutics, which develops novel inhibitors in the neurocognitive space, and N8 Medical, Inc., which is commercializing novel small molecule compounds that mimic naturally occurring antimicrobial peptides. Earlier in his career, Mr. Richards served in operational and legal capacities for family office funds and was an associate at Latham & Watkins, a multinational law firm.
The expansion of the Clarametyx Board of Directors with Larry Edwards as an Independent Director reflects the Company’s accelerated development priorities. Mr. Edwards brings more than 25 years of pharmaceutical and biotech experience as a seasoned operational and commercial Leader. He is currently President and CEO of La Jolla Pharmaceutical and Tetraphase Pharmaceuticals, based in Boston, Mass., following tenures in commercial leadership with Cubist Pharmaceuticals and Merck & Co. In addition to these appointments, co-Founder and Chief Financial Officer Peter Kleinhenz will also step back from his management role to become a board member.
“The technology we are advancing provides a rare opportunity to make a real and dynamic impact on the challenge of serious bacterial infections, and I am honored to serve as the CEO to champion this paradigm-shifting approach,” said Richards. “We have important work ahead to optimize our newly received funding and advance our programs toward clinical development. I am eager to work closely with our talented leadership team and passionate Board of Directors during this important time in our company’s journey.”
About Clarametyx Biosciences
Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response or antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms. Its lead candidate, CMTX-101, is a humanized monoclonal antibody in preclinical development for hospital-acquired pneumonia. For more information, visit us on the web or on LinkedIn.
Source Business Wire Health: Pharmaceutical News